1. Home
  2. IZEA vs ICCC Comparison

IZEA vs ICCC Comparison

Compare IZEA & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IZEA Worldwide Inc.

IZEA

IZEA Worldwide Inc.

HOLD

Current Price

$2.58

Market Cap

50.3M

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$9.93

Market Cap

93.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IZEA
ICCC
Founded
2006
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.3M
93.1M
IPO Year
2010
1995

Fundamental Metrics

Financial Performance
Metric
IZEA
ICCC
Price
$2.58
$9.93
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 34.7K
12.0K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 100.00
53.85
EPS
N/A
★ 0.41
Revenue
$20,099,695.00
★ $26,493,169.00
Revenue This Year
$20.81
N/A
Revenue Next Year
$14.86
N/A
P/E Ratio
★ N/A
$24.10
Revenue Growth
N/A
★ 51.64
52 Week Low
$2.38
$4.52
52 Week High
$5.86
$12.10

Technical Indicators

Market Signals
Indicator
IZEA
ICCC
Relative Strength Index (RSI) 33.55 47.52
Support Level N/A $9.39
Resistance Level $3.85 $10.16
Average True Range (ATR) 0.12 0.29
MACD -0.00 0.03
Stochastic Oscillator 33.92 67.66

Price Performance

Historical Comparison
IZEA
ICCC

About IZEA IZEA Worldwide Inc.

IZEA Worldwide Inc is a full-service creator economy agency powered by proprietary ZED technology, with a mission to make Creator Economy solutions for marketers. It does this by lighting up the Creator Economy with IZEA's strategies, campaigns, and solutions that build brands and drive demand. Since launching the industry's first-ever influencer marketing platform in 2006, IZEA has facilitated nearly 4 million collaborations between brands and creators.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: